{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/LBRX",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# LB PHARMACEUTICALS INC (NASDAQ: LBRX) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is LB PHARMACEUTICALS INC, listed on NASDAQ under ticker LBRX, with ISIN US50180M1080. The LEI is not on the record. The security type is Corporate, the segment is not on the record, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is United States, Delaware. The issuer is listed and not halted.\n\n## The disclosure read\n\nThe record holds 71 filings in the twelve months to 2026-11-08, across 36 filing days. The median gap between filing days is 7 days. The latest filing is dated 2026-11-05, 3 days before the record date, and is of type results. The exchange median for NASDAQ is 6.0 days of cadence gap, 52 filings and 5.0 days of latency across 4359 issuers. The sector median for 2834 Pharmaceutical Preparations is 6.0 days of cadence gap, 63.0 filings and 4.0 days of latency across 526 issuers. By type, the window holds 3 agm_egm, 5 corporate_news, 5 director_change, 17 directors_dealings, 11 prospectus, 22 regulatory_filing and 8 results filings.\n\n## Auditor\n\nThe auditor of record is not on the record, because the latest annual report cover carries no dei:AuditorName tag. The auditor location is not on the record. The market's record holds no auditor changes for the issuer.\n\n## Events and halts\n\nThe record holds no listing, delisting or name change lines for the issuer. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag is clear: listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable under rule version acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, because the chapter's orderability section carries no client categories, so the outcome cannot name its client category. The chapter is as of 2026-11-04.\n\n## Coverage\n\nThe issuer's investor-relations page names 12 research houses: BMO Capital Markets, Canaccord Genuity, Clear Street, Craig-Hallum, Guggenheim, H.C. Wainwright, Leerink, Needham, Piper Sandler, Roth Capital Partners, Stifel and Wolfe Research.\n\n## Open research\n\nNo openly published research notes were found for the issuer, so the record holds none.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe issuer's years sealed are 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.\n\n## Sources\n\n8 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)\n- https://data.sec.gov/submissions/CIK0001691082.json (identity.jurisdiction)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/LBRX (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://ir.lbpharma.com/investors/stock-information/ (coverage)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/LBRX (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "market": "US",
    "reason": "no dei:AuditorName tag on the latest annual report cover (foreign private issuers and older filings carry none)",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "US",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "US",
    "state": "not_on_record"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/LBRX",
  "coverage": {
   "count": 12,
   "houses": [
    {
     "analyst": "Malcolm Hoffman",
     "house": "BMO Capital Markets",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.lbpharma.com/investors/stock-information/",
     "state": "sourced"
    },
    {
     "analyst": "Sumant Kulkarni",
     "house": "Canaccord Genuity",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.lbpharma.com/investors/stock-information/",
     "state": "sourced"
    },
    {
     "analyst": "Kaveri Pohlman",
     "house": "Clear Street",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.lbpharma.com/investors/stock-information/",
     "state": "sourced"
    },
    {
     "analyst": "Adam Vogel",
     "house": "Craig-Hallum",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.lbpharma.com/investors/stock-information/",
     "state": "sourced"
    },
    {
     "analyst": "Delma Caiati",
     "house": "Guggenheim",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.lbpharma.com/investors/stock-information/",
     "state": "sourced"
    },
    {
     "analyst": "Raghuram Selvaraju",
     "house": "H.C. Wainwright",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.lbpharma.com/investors/stock-information/",
     "state": "sourced"
    },
    {
     "analyst": "Marc Goodman",
     "house": "Leerink",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.lbpharma.com/investors/stock-information/",
     "state": "sourced"
    },
    {
     "analyst": "Ami Fadia",
     "house": "Needham",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.lbpharma.com/investors/stock-information/",
     "state": "sourced"
    },
    {
     "analyst": "Yasmeen Rahimi",
     "house": "Piper Sandler",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.lbpharma.com/investors/stock-information/",
     "state": "sourced"
    },
    {
     "analyst": "Boobalan Pachaiyappan",
     "house": "Roth Capital Partners",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.lbpharma.com/investors/stock-information/",
     "state": "sourced"
    },
    {
     "analyst": "Paul Matteis",
     "house": "Stifel",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.lbpharma.com/investors/stock-information/",
     "state": "sourced"
    },
    {
     "analyst": "Rudy Li",
     "house": "Wolfe Research",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.lbpharma.com/investors/stock-information/",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://ir.lbpharma.com/investors/stock-information/",
     "result": "read: 12 of 24 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "agm_egm": 3,
    "corporate_news": 5,
    "director_change": 5,
    "directors_dealings": 17,
    "prospectus": 11,
    "regulatory_filing": 22,
    "results": 8
   },
   "cadence_median_gap_days": 7,
   "filing_days": 36,
   "filings": 71,
   "latency_days": 3,
   "latest": [
    {
     "category": "10-Q",
     "date": "2026-11-05",
     "source": "https://www.sec.gov/Archives/edgar/data/1691082/000119312526449994/lbrx-20260930.htm",
     "title": "10-Q — 10-Q",
     "type": "results"
    },
    {
     "category": "8-K",
     "date": "2026-11-05",
     "source": "https://www.sec.gov/Archives/edgar/data/1691082/000119312526449887/d167920d8k.htm",
     "title": "8-K — 8-K (items 2.02,9.01)",
     "type": "results"
    },
    {
     "category": "4",
     "date": "2026-10-13",
     "source": "https://www.sec.gov/Archives/edgar/data/1691082/000215026726000005/xslF345X06/form4-10132026_041001.xml",
     "title": "4",
     "type": "directors_dealings"
    },
    {
     "category": "4",
     "date": "2026-10-13",
     "source": "https://www.sec.gov/Archives/edgar/data/1691082/000174637226000007/xslF345X06/form4-10132026_041004.xml",
     "title": "4",
     "type": "directors_dealings"
    },
    {
     "category": "SCHEDULE 13G/A",
     "date": "2026-10-13",
     "source": "https://www.sec.gov/Archives/edgar/data/1691082/000001961726000360/xslSCHEDULE_13G_X02/primary_doc.xml",
     "title": "SCHEDULE 13G/A",
     "type": "regulatory_filing"
    }
   ],
   "latest_filing_date": "2026-11-05",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/LBRX",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "read_by": "SEC Fails-to-Deliver data (CUSIP for the symbol) · ISIN = US + CUSIP + ISO 6166 check digit",
    "read_date": "2026-09-18",
    "read_date_basis": "last_seen",
    "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data",
    "state": "sourced",
    "value": "US50180M1080"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001691082.json",
    "state": "sourced",
    "value": "United States — Delaware"
   },
   "lei": {
    "market": "US",
    "reason": "no GLEIF record with the exact legal name in jurisdiction US-DE",
    "state": "not_on_record"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001691082.json",
    "state": "sourced",
    "value": "LB PHARMACEUTICALS INC"
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001691082.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001691082.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "LBRX"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:b1a3ceff6f7ea573e1cc1433cf27153466ef64441ae09f3a321f8b4166e83d30",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/LBRX",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:b1a3ceff6f7ea573e1cc1433cf27153466ef64441ae09f3a321f8b4166e83d30",
 "path": "/us/NASDAQ/LBRX",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is LB PHARMACEUTICALS INC, listed on NASDAQ under ticker LBRX, with ISIN US50180M1080. The LEI is not on the record. The security type is Corporate, the segment is not on the record, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is United States, Delaware. The issuer is listed and not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 71 filings in the twelve months to 2026-11-08, across 36 filing days. The median gap between filing days is 7 days. The latest filing is dated 2026-11-05, 3 days before the record date, and is of type results. The exchange median for NASDAQ is 6.0 days of cadence gap, 52 filings and 5.0 days of latency across 4359 issuers. The sector median for 2834 Pharmaceutical Preparations is 6.0 days of cadence gap, 63.0 filings and 4.0 days of latency across 526 issuers. By type, the window holds 3 agm_egm, 5 corporate_news, 5 director_change, 17 directors_dealings, 11 prospectus, 22 regulatory_filing and 8 results filings.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is not on the record, because the latest annual report cover carries no dei:AuditorName tag. The auditor location is not on the record. The market's record holds no auditor changes for the issuer.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting or name change lines for the issuer. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag is clear: listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable under rule version acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, because the chapter's orderability section carries no client categories, so the outcome cannot name its client category. The chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The issuer's investor-relations page names 12 research houses: BMO Capital Markets, Canaccord Genuity, Clear Street, Craig-Hallum, Guggenheim, H.C. Wainwright, Leerink, Needham, Piper Sandler, Roth Capital Partners, Stifel and Wolfe Research.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found for the issuer, so the record holds none.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The issuer's years sealed are 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "8 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001691082.json"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/LBRX"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://ir.lbpharma.com/investors/stock-information/"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/LBRX"
  }
 ],
 "title": "LB PHARMACEUTICALS INC (LBRX) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}